Ebb & Flow

Three highly anticipated sets of Phase III data were announced last week: for exenatide LAR to treat Type II diabetes, for Viveta treprostinil to treat pulmonary arterial hypertension and for Orplatna satraplatin to treat prostate cancer.

One was a blow up, with predictable results for GPC (FSE:GPC; GPCB). Of the two successes, only United Therapeutics (UTHR) was rewarded by the market, while Amylin (AMLN) was penalized for not rewarding expectations...